A clinical-laboratory nomogram integrating inflammatory, metabolic and proliferative markers to predict refractory disease or early relapse in diffuse large B-cell lymphoma
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background First-line R-CHOP immunochemotherapy controls diffuse large B-cell lymphoma (DLBCL) in most patients, but 30%–40% develop primary refractory disease or early relapse, both with poor survival. The composite endpoint of refractory disease or early relapse (R/ER) was predefined, as both reflect early treatment failure. The International Prognostic Index captures tumor biology only partially, and no bedside tool integrates routine inflammatory, metabolic, and proliferative markers. We developed and internally validated a routine-marker nomogram to predict R/ER after first-line immunochemotherapy and quantified predictor contributions. Materials and methods In this retrospective single-center study, 342 patients were randomly split 7:3 into training ( n = 239) and internal validation ( n = 103) cohorts. Predictors were screened by univariate analysis ( P < 0.05), followed by LASSO and multivariable logistic regression. The logistic model was compared with random forest (RF) and support vector machine (SVM) models by ROC-AUC, calibration, and decision curve analysis; hyperparameters were tuned by training-set cross-validation. SHAP analysis quantified predictor contributions on the log-odds scale. Results Elevated lactate dehydrogenase (LDH), β 2-microglobulin ( β 2-MG), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and Ki-67, with reduced lymphocyte-to-monocyte ratio (LMR), independently predicted R/ER (all P < 0.05). Logistic regression had the highest AUC (0.815, 95% CI 0.747–0.883 in training; 0.776, 0.660–0.891 in validation), with no significant between-model AUC differences (DeLong P = 0.68 vs. RF, P = 0.08 vs. SVM in training; all P > 0.05 in validation). Calibration slope and intercept were 0.97 and 0.03 in training and 0.93 and 0.07 in validation; net benefit at thresholds 0.2, 0.3, and 0.4 was 0.26, 0.19, and 0.13 in training and 0.22, 0.16, and 0.10 in validation. The logistic model was selected for parsimony and interpretability. SHAP ranked predictors as Ki-67, PLR, LDH, NLR, β 2-MG, and LMR, forming a six-factor nomogram with acceptable discrimination and calibration. Conclusion A six routine-marker nomogram showed acceptable discrimination and calibration for R/ER after first-line immunochemotherapy in this single-center cohort. As it was only internally validated and not compared with IPI, NCCN-IPI, or R-IPI, it remains exploratory and requires multicenter prospective external validation before clinical use.
Source: Frontiers in Medicine
Authors: Shuang Li(Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing), Quanzhong Yang(Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – review & editing), Weikai Zhang(Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – review & editing), Wei Chen(Investigation, Methodology, Resources, Validation, Visualization, Writing – review & editing)
Institution: Luoyang Polytechnic
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Keywords: diffuse large B-cell lymphoma, refractory disease, early recurrence, nomogram, R-CHOP, prognostic factors, lactate dehydrogenase, beta2-microglobulin, Ki-67, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, metabolic biomarkers, inflammatory markers
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7234105939
